Prescription Drug Information: Rosuvastatin Calcium (Page 4 of 7)


Rosuvastatin calcium USP is a synthetic lipid-lowering agent for oral administration.

The chemical name for rosuvastatin calcium USP is bis[(E)-7-[4- (4-fluorophenyl)-6-isopropyl-2 [methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S) -3,5-dihydroxyhept-6-enoic acid] calcium salt with the following structural formula:

(click image for full-size original)

The empirical formula for rosuvastatin calcium USP is (C22 H27 FN3 O6 S)2 Ca and the molecular weight is 1001.14. Rosuvastatin calcium USP is a white amorphous powder that is sparingly soluble in water and methanol, and slightly soluble in ethanol. Rosuvastatin calcium is a hydrophilic compound with a partition coefficient (octanol/water) of 0.13 at pH of 7.0.

Rosuvastatin Calcium USP for oral administration contain 5, 10, 20, or 40 mg of rosuvastatin and the following inactive ingredients: Each tablet contains: crospovidone, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, titanium dioxide and triacetin. Additionally, the 5 mg tablet contains ferric oxide yellow and the 10 mg, 20 mg and 40 mg tablets contain ferric oxide red.


12.1 Mechanism of Action

Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor of cholesterol. In vivo studies in animals, and in vitro studies in cultured animal and human cells have shown rosuvastatin to have a high uptake into, and selectivity for, action in the liver, the target organ for cholesterol lowering. In in vivo and in vitro studies, rosuvastatin produces its lipid-modifying effects in two ways. First, it increases the number of hepatic LDL receptors on the cell-surface to enhance uptake and catabolism of LDL. Second, rosuvastatin inhibits hepatic synthesis of VLDL, which reduces the total number of VLDL and LDL particles.

12.3 Pharmacokinetics


In clinical pharmacology studies in man, peak plasma concentrations of rosuvastatin were reached 3 to 5 hours following oral dosing. Both Cmax and AUC increased in approximate proportion to rosuvastatin dose. The absolute bioavailability of rosuvastatin is approximately 20%.

Administration of rosuvastatin with food did not affect the AUC of rosuvastatin.

The AUC of rosuvastatin does not differ following evening or morning drug administration.


Mean volume of distribution at steady-state of rosuvastatin is approximately 134 liters. Rosuvastatin is 88% bound to plasma proteins, mostly albumin. This binding is reversible and independent of plasma concentrations.


Rosuvastatin is primarily eliminated by excretion in the feces. The elimination half-life of rosuvastatin is approximately 19 hours.


Rosuvastatin is not extensively metabolized; approximately 10% of a radiolabeled dose is recovered as metabolite. The major metabolite is N-desmethyl rosuvastatin, which is formed principally by cytochrome P450 \ 2C9, and in vitro studies have demonstrated that N-desmethyl rosuvastatin has approximately one-sixth to one-half the HMG-CoA reductase inhibitory activity of the parent compound. Overall, greater than 90% of active plasma HMG-CoA reductase inhibitory activity is accounted for by the parent compound.


Following oral administration, rosuvastatin and its metabolites are primarily excreted in the feces (90%). After an intravenous dose, approximately 28% of total body clearance was via the renal route, and 72% by the hepatic route.

Specific Populations

Racial or Ethnic Groups

A population pharmacokinetic analysis revealed no clinically relevant differences in pharmacokinetics among Caucasian, Hispanic, and Black or Afro-Caribbean groups. However, pharmacokinetic studies, including one conducted in the US, have demonstrated an approximate 2-fold elevation in median exposure (AUC and Cmax ) in Asian subjects when compared with a Caucasian control group.

Male and Female Patients

There were no differences in plasma concentrations of rosuvastatin between men and women.

Pediatric use information for patients ages 8 to less than 10 years is approved for AstraZeneca’s CRESTOR (rosuvastatin calcium) tablets. However, due to AstraZeneca’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

Geriatric Patients

There were no differences in plasma concentrations of rosuvastatin between the nonelderly and elderly populations (age ≥65 years).

Patients with Renal Impairment

Mild to moderate renal impairment (CLcr ≥30 mL/min/1.73 m2) had no influence on plasma concentrations of rosuvastatin. However, plasma concentrations of rosuvastatin increased to a clinically significant extent (about 3- fold) in patients with severe renal impairment (CLcr <30 mL/min/1.73 m2) not receiving hemodialysis compared with healthy subjects (CLcr >80 mL/min/1.73 m2).


Steady-state plasma concentrations of rosuvastatin in patients on chronic hemodialysis were approximately 50% greater compared with healthy volunteer subjects with normal renal function.

Patients with Hepatic Impairment

In patients with chronic alcohol liver disease, plasma concentrations of rosuvastatin were modestly increased.

In patients with Child-Pugh A disease, Cmax and AUC were increased by 60% and 5%, respectively, as compared with patients with normal liver function. In patients with Child-Pugh B disease, Cmax and AUC were increased 100% and 21%, respectively, compared with patients with normal liver function.

Drug Interactions Studies

Rosuvastatin clearance is not dependent on metabolism by cytochrome P450 3A4 to a clinically significant extent.

Rosuvastatin is a substrate for certain transporter proteins including the hepatic uptake transporter organic anion-transporting polyprotein 1B1 (OATP1B1) and efflux transporter breast cancer resistance protein (BCRP). Concomitant administration of rosuvastatin with medications that are inhibitors of these transporter proteins (e.g. cyclosporine, certain HIV protease inhibitors) may result in increased rosuvastatin plasma concentrations [see Dosage and Administration(2.4) and Drug Interactions (7.1, 7.3)]

Table 4. Effect of Coadministered Drugs on Rosuvastatin Systemic Exposure
1 Single dose unless otherwise noted.
2 Clinically significant [seeDosage and Administration(2) and Warnings and Precautions(5) ]
3 Mean ratio with 90% CI (with/without coadministered drug, e.g., 1= no change, 0.7 = 30% decrease, 11=11 fold increase in exposure)

Coadministered drug and dosing regimen


Mean Ratio (ratio with/without coadministered drug) No Effect = 1.0

Dose (mg)1

Change in AUC

Change in Cmax

Cyclosporine – stable dose required (75 mg to 200 mg BID)

10 mg QD for 10 days



Atazanavir/ritonavir combination 300 mg/100 mg QD for 8 days

10 mg



Simeprevir 150 mg QD, 7 days

10 mg, single dose

2.82 (2.3 to 3.4)3

3.22 (2.6 to 3.9)3

Lopinavir/ritonavir combination 400 mg/100 mg BID for 17 days

20 mg QD for 7 days

2.12 (1.7 to 2.6)3

52 (3.4 to 6.4)3

Gemfibrozil 600 mg BID for 7 days

80 mg

1.92 (1.6 to 2.2)3

2.22 (1.8 to 2.7)3

Eltrombopag 75 mg QD, 5 days

10 mg

1.6 (1.4 to 1.7)3

2 (1.8 to 2.3)3

Darunavir 600 mg/ritonavir 100 mg BID, 7 days

10 mg QD for 7 days

1.5 (1.0 to 2.1)3

2.4 (1.6 to 3.6)3

Tipranavir/ritonavir combination 500 mg/200mg BID for 11 days

10 mg

1.4 (1.2 to 1.6)3

2.2 (1.8 to 2.7)3

Dronedarone 400 mg BID

10 mg


Itraconazole 200 mg QD, 5 days

10 mg or 80 mg

1.4 (1.2 to 1.6)3 1.3 (1.1 to 1.4)3

1.4 (1.2 to 1.5)3 1.2 (0.9 to 1.4)3

Ezetimibe 10 mg QD, 14 days

10 mg QD for 14 days

1.2 (0.9 to 1.6)3

1.2 (0.8 to 1.6)3

Fosamprenavir/ritonavir 700 mg/100 mg BID for 7 days

10 mg



Fenofibrate 67 mg TID for 7 days

10 mg

1.2 (1.1 to 1.3)3

Rifampicin 450 mg QD, 7 days

20 mg

Aluminum & magnesium hydroxide combination antacid Administered simultaneously Administered 2 hours apart

40 mg 40 mg

0.52 (0.4 to 0.5)3 0.8 (0.7 to 0.9)3

0.52 (0.4 to 0.6)3 0.8 (0.7 to 1.0)3

Ketoconazole 200 mg BID for 7 days

80 mg

1.0 (0.8 to 1.2)3

1.0 (0.7 to 1.3)3

Fluconazole 200 mg QD for 11 days

80 mg

1.1 (1.0 to 1.3)3

1.1 (0.9 to 1.4)3

Erythromycin 500 mg QID for 7 days

80 mg

0.8 (0.7 to 0.9)3

0.7 (0.5 to 0.9)3

Table 5. Effect of Rosuvastatin Coadministration on Systemic Exposure to Other Drugs
EE = ethinyl estradiol, NG = norgestrel
1 Clinically significant pharmacodynamic effects [seeWarnings and Precautions(5.3) ]
2 Mean ratio with 90% CI (with/without coadministered drug, e.g., 1= no change, 0.7=30% decrease, 11=11-fold increase in exposure)

Rosuvastatin Dosage Regimen

Coadministered Drug

Mean Ratio (ratio with/without coadministered drug) No Effect = 1.0

Name and Dose

Change in AUC

Change in Cmax

40 mg QD for 10 days

Warfarin 1 25 mg single dose

R-Warfarin 1.0 (1.0 to 1.1)2 S-Warfarin 1.1 (1.0 to 1.1)2

R-Warfarin 1.0 (0.9 to 1.0)2 S-Warfarin 1.0 (0.9 to1.1)2

40 mg QD for 12 days

Digoxin 0.5 mg single dose

1.0 (0.9 to 1.2)2

1.0 (0.9 to 1.2)2

40 mg QD for 28 days

Oral Contraceptive (ethinyl estradiol 0.035 mg & norgestrel 0.180, 0.215 and 0.250 mg) QD for 21 Days

EE 1.3 (1.2 to 1.3)2 NG 1.3 (1.3 to 1.4)2

EE 1.3 (1.2 to 1.3)2 NG 1.2 (1.1 to 1.3)2 provides trustworthy package insert and label information about marketed prescription drugs as submitted by manufacturers to the U.S. Food and Drug Administration. Package information is not reviewed or updated separately by Every individual prescription drug label and package insert entry contains a unique identifier which can be used to secure further details directly from the U.S. National Institutes of Health and/or the FDA.

Medication Sections

Medication Information by RSS

As a leading independent provider of trustworthy medication information, we source our database directly from the FDA's central repository of drug labels and package inserts under the Structured Product Labeling standard. provides the full prescription-only subset of the FDA's repository. Medication information provided here is not intended as a substitute for direct consultation with a qualified health professional.

Terms of Use | Copyright © 2020. All Rights Reserved.